Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report?Zacks Investment Research • 03/14/20
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/13/20
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 MutationGlobeNewsWire • 12/16/19
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase DeficiencyGlobeNewsWire • 12/09/19
Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)GlobeNewsWire • 12/09/19
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 ResultsGlobeNewsWire • 12/08/19
Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for InvestorsThe Motley Fool • 11/27/19
Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade GliomaGlobeNewsWire • 11/22/19
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesGlobeNewsWire • 11/13/19
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual MeetingGlobeNewsWire • 11/06/19
Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/31/19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted TumorsGlobeNewsWire • 10/27/19
Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International ConferenceGlobeNewsWire • 10/09/19
Agios Pharmaceuticals (AGIO) Down 11.2% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 08/31/19
Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/01/19